Evogene Ltd. EVGN
Agricultural Chemicals · data as of November 13, 2026
Evogene Ltd. (EVGN) is a industrial company listed in the US with a market value of about $6M. In fiscal year 2025 it had revenue of $4M and net income of -$8M, a net margin of -220.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 30% a year, a 5-year average ROIC of -89%.
About Evogene
Evogene is listed in the US and classified in agricultural chemicals. Revenue went from $11M in 2015 to $4M in 2025, a decline of about 10.1% a year. It was profitable in 0 of the last 10 years in our data.
Score: 1.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $6M | $3M | $2M | $930000 | $1M | $753000 | $2M | $3M | $7M |
| Net income | -$8M | -$16M | -$24M | -$27M | -$28M | -$23M | -$18M | -$21M | -$21M | -$20M |
| Free cash flow | -$14M | -$20M | -$22M | -$25M | -$26M | -$20M | -$19M | -$16M | -$17M | -$13M |
| EPS (diluted) | $-0.54 | $-1.04 | $-1.51 | $-1.69 | $-1.76 | $-1.48 | $-1.15 | $-1.31 | $-1.32 | $-1.24 |
| Net margin | -220.2% | -295.6% | -800.8% | -1590.3% | -2988.5% | -2247.5% | -2405.3% | -1188.2% | -616.3% | -299.6% |
| ROIC | — | — | -145.7% | -76.2% | -45.6% | -42.6% | -33.4% | -31.6% | -25.0% | -19.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Evogene pay a dividend?
Not currently.
Is Evogene a good stock to buy?
We do not give buy or sell advice. Evogene scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.